Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

Last year, Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a single injection every six months.

Gilead Sciences has said it plans to challenge patents held by the US government on the use of its HIV drug Truvada for pre-exposure prophylaxis (PrEP). In a move that will incense critics who ...

Many trans people considering using the HIV prevention medication PrEP have concerns about side effects and drug interactions, and in particular whether PrEP drugs might interfere with ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...